BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Presentation (August 2021)
6 slides from BeyondSpring's investor presentation, Aug 26, 2021
Slide 1: Plinabulin Partnership in Greater China
Plinabulin Partnership in Greater China – Exclusive Commercial and Co-development Agreement between BeyondSpring Subsidiary “Wanchunbulin” and “Hengrui” August 26, 2021| NASDAQ: BYSI 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: Hengrui is the Ideal Partner for Plinabulin in Greater China
Hengrui is the Ideal Partner for Plinabulin in Greater China Exceptional synergy between plinabulin and Hengrui pipeline ➢ Hengrui is the leader in oncology product R&D and commercialization in China • Established in 1970; Listed on Shanghai Stock Exchange in 2000 (Shanghai stock exchange ticker: 60
Slide 4: Hengrui Partnership Supports Key Commercialization Goals in China
Hengrui Partnership Supports Key Commercialization Goals in China Manages commercialization risk and optimizes return on plinabulin franchise • Leverages existing infrastructure of leading oncology player • Minimizes launch investment and risk • Optimizes near-term return through performance-related
Slide 5: Hengrui and Wanchunbulin Partnership in Greater China - Key Terms
Hengrui and Wanchunbulin Partnership in Greater China - Key Terms (BeyondSpring Inc. owns 58% of Wanchunbulin) Key Synergies Allow for a Mutually Beneficial Deal Hengrui: Plinabulin Rights in Greater China Terms (est. USD*) • Exclusive commercialization of all • Wanchunbulin receives $30M upfront +
Slide 6: www.beyondspringpharma.com
www.beyondspringpharma.com 6